|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ RecruitingNot Applicable 评价 SKG0106 用于治疗新生血管性(湿性)年龄相关性黄斑变性患者的前瞻性、非干预、多中心的长期随访研究
[Translation] A prospective, non-interventional, multicenter, long-term follow-up study evaluating SKG0106 for the treatment of patients with neovascular (wet) age-related macular degeneration
[Translation] To evaluate the long-term safety and long-term efficacy of SKG0106.
100 Clinical Results associated with Lanyue Biomedical Technology (Hangzhou) Co., Ltd.
0 Patents (Medical) associated with Lanyue Biomedical Technology (Hangzhou) Co., Ltd.
100 Deals associated with Lanyue Biomedical Technology (Hangzhou) Co., Ltd.
100 Translational Medicine associated with Lanyue Biomedical Technology (Hangzhou) Co., Ltd.